Quanterix Corp (NASDAQ:QTRX) Chairman E Kevin Hrusovsky sold 2,940 shares of the firm’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $18.46, for a total value of $54,272.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

E Kevin Hrusovsky also recently made the following trade(s):

  • On Friday, November 16th, E Kevin Hrusovsky sold 4,000 shares of Quanterix stock. The stock was sold at an average price of $16.67, for a total value of $66,680.00.
  • On Thursday, November 1st, E Kevin Hrusovsky sold 2,829 shares of Quanterix stock. The stock was sold at an average price of $17.97, for a total value of $50,837.13.
  • On Tuesday, October 2nd, E Kevin Hrusovsky sold 2,995 shares of Quanterix stock. The stock was sold at an average price of $20.91, for a total value of $62,625.45.
  • On Wednesday, September 5th, E Kevin Hrusovsky sold 17,909 shares of Quanterix stock. The shares were sold at an average price of $14.53, for a total value of $260,217.77.

NASDAQ:QTRX traded down $0.40 during trading hours on Thursday, hitting $17.99. 6,613 shares of the company’s stock traded hands, compared to its average volume of 73,508. The firm has a market capitalization of $408.22 million and a price-to-earnings ratio of -2.17. Quanterix Corp has a 52 week low of $13.00 and a 52 week high of $24.81. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.76 and a current ratio of 4.11.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Wednesday, November 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). The business had revenue of $10.59 million for the quarter, compared to the consensus estimate of $9.57 million. Quanterix had a negative net margin of 88.72% and a negative return on equity of 52.35%. Equities analysts forecast that Quanterix Corp will post -1.21 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on QTRX shares. Canaccord Genuity started coverage on Quanterix in a research note on Wednesday, October 10th. They set a “buy” rating and a $27.00 price objective for the company. Zacks Investment Research raised Quanterix from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Quanterix presently has an average rating of “Buy” and a consensus price target of $26.67.

Large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new stake in Quanterix during the second quarter valued at $117,000. Teachers Advisors LLC bought a new stake in Quanterix during the third quarter valued at $219,000. Granite Investment Partners LLC bought a new stake in Quanterix during the third quarter valued at $346,000. First Republic Investment Management Inc. bought a new stake in Quanterix during the second quarter valued at $235,000. Finally, PNC Financial Services Group Inc. bought a new stake in Quanterix during the third quarter valued at $428,000. 49.62% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Quanterix Corp (QTRX) Chairman Sells 2,940 Shares of Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2018/12/06/insider-selling-quanterix-corp-qtrx-chairman-sells-2940-shares-of-stock.html.

About Quanterix

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.

Read More: Dividend Stocks – Are They Right For You?

Insider Buying and Selling by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.